Large increase now becomes biggish! Then we have to make assumptions as to whether he's talking percentages or bo. If we note that the last RISC upgraded CNE's 385mbo to 560mbo that is a 175mbo upgrade. The inference I get from FAR and now Malcy is that the increase will not be as large as the last increase. The last increase was almost 50% (175mbo). A 30% increase on the 560mbo would be 168mbo which you could argue that in bo is the same size increase in bo as the prior RISC. That would be a large increase in anyone's books. Biggest, I'm not sure. Would Malcy be referring to a 30% increase in 2c as biggish? If the case then 2c climbs to 730mbo then FAR's equity climbs to 110mbo. FAR's share price has averaged 8c with 84mbo project equity (US$3.27bo 2c). Assuming FAR's project equity climbs to 110mbo (2c 730mbo) then if the market places the same valuation on FAR as it has been doing up to the COP induced sell off then the FAR share price would be fully valued at 10.5c (US3.27bo 2c 110mbo) .
I just know I'm going to get irate posts with the above analogy!
- Forums
- ASX - By Stock
- FAR
- Malcy's email
Malcy's email, page-15
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add FAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
49.5¢ |
Change
-0.010(1.98%) |
Mkt cap ! $45.74M |
Open | High | Low | Value | Volume |
50.5¢ | 50.5¢ | 49.5¢ | $26.98K | 54.03K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 20223 | 49.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
50.5¢ | 611 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20223 | 0.495 |
1 | 2000 | 0.485 |
2 | 28930 | 0.480 |
2 | 70000 | 0.475 |
2 | 78150 | 0.470 |
Price($) | Vol. | No. |
---|---|---|
0.505 | 611 | 1 |
0.510 | 59999 | 2 |
0.525 | 69690 | 1 |
0.530 | 30000 | 1 |
0.535 | 30000 | 1 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
FAR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online